Pfiz­er re­veals de­lays across the board for its clin­i­cal gene ther­a­py pro­grams

At JP Mor­gan 2020, a year af­ter tak­ing the reins at Pfiz­er, Al­bert Bourla claimed the com­pa­ny was poised to be­come a leader in gene ther­a­py. He’s since thrown hun­dreds of mil­lions of dol­lars at those plans, in­clud­ing a $630 mil­lion deal just last month for two of Voy­ager’s AAVs.

Now, it ap­pears Phase III read­outs are fur­ther away than Bourla had hoped.

Set­backs have re­sult­ed in de­lays across all three of Pfiz­er’s clin­i­cal gene ther­a­py pro­grams, the com­pa­ny re­vealed in its Q3 re­sults on Tues­day — in­clud­ing one tri­al which was paused over safe­ty con­cerns.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER